Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

UPDATED: Endo finally wins a Low-T drug nod, but safety dispute could snarl its launch

06.03.2014 / Fierce Pharma

For Endo's testosterone therapy Aveed, the third time wasn't the charm with the FDA–but the fourth time was. After a trio of rejections, the FDA has given the thumbs up to the Low-T drug, and the Malvern, PA-based company expects to launch it this month. But amid the safety questions surrounding testosterone drugs, doing so may not be so easy.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: